SCHEMBL7003401

SCHEMBL7003401

CCOC(=N)C(=N)OCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
LMNA P02545 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
ALOX15 P16050 1/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
SOAT1 P35610 1/20 0.40
TRPA1 O75762 1/20 0.36
DGAT1 O75907 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
TSHR P16473 1/20 0.31
GLO1 Q04760 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25079138 0.83
SCHEMBL14067377 0.81
SCHEMBL554111 0.78 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL21500725 0.78 CA12 (0.43) ALDH1A1LMNAHSD17B10CA12CA1
SCHEMBL10312391 0.78
SCHEMBL1544765 0.78
SCHEMBL5462451 0.77
Hydrochloric Acid SCHEMBL2935026 0.76 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL10519040 0.76
SCHEMBL15152362 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361644-B2 Specific antagonist for both E- and P-selectins GLYCOMIMETICS, INC. (US) 2008-04-22 US disclosed
EP-1763533-B1 SPECIFIC ANTAGONIST FOR BOTH E- AND P-SELECTINS GLYCOMIMETICS INC (US) 2008-01-09 EP disclosed
EP-1189889-B1 COMPOSITIONS AND METHODS FOR INHIBITING CELL DEATH ELAN PHARMA INT LTD (IE) 2003-12-17 EP disclosed
US-6541486-B1 Used for treating ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation. ELAN PHARMA INTERNATIONAL LTD. (IE) 2003-04-01 US disclosed